Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by NewToInvesting7on Apr 06, 2021 10:03am
120 Views
Post# 32940880

RE:My take for what its worth.

RE:My take for what its worth.Thanks, Bully.  This is very informative.

I do however, have a few questions that I wish James would address, but know that he may not/cannot address in a NR:

1.  Do we know what exactly StageZero is acquiring?  What are the assets and iabilities within these 2 entities?  Are the acquired entities profitable?  
2.  You focused on the potential additional revenues that would potentially now be 100% attributed to StageZero.  Do we know that the additional revenues from HC will cover the the additional expenses due to the HC 'merger'?  Are there any sort of IP fees or other non-contingent payments that StageZero will have to pay to the parent company of HC?
3.  It appears that we are getting some pretty established and knowledgeable members from HC.  How much will these individuals cost StageZero annually?

I do have many other questions, but I believe the above questions would add much clarity for me personally.

Off topic slightly, has anyone seen any of StageZero's Aristotle advertisments?  I have not seen anything on its website, LinkedIn, or Twitter, but hope to see something in the mainstream media soon.

Cheers!



Bully88 wrote: For those of you Holding strong, I commend you.

This has been quite the test of patience.

I myself found myself very frustrated with this past weekends performance by Mr. Tripp.

Momentum riding us to 52 week highs, then you go and botch your highly awaited Holy Grail 20 years of work technology?  

In my opinion, it should have went like this.

News Release pre market thursday - ARISTOTLE Released to Comercial.

News Release pre market thursday - SZLS Purchases Health Care clinics with 3 Locations serving thousands of patients

News Release post market Thursday - Q4 Earnings close to 3 million and climbing.

That in my opinion, would have sent the momentum onward and upward and kept this train rolling.

However, as stated many times in previous posts. this is a risk 50% or gain 100's to 1000's of %

The fact that he botched this rollout completely was extremely disapointing which brought the risk side out and share price tumbling almost 50%.

What a wild ride that was.

After spending the weekend going through everything as much as one can I have come to the opinion that this rollout is not bad at all. In fact it is quite a positive move in the right direction.

I started looking into Care Oncology and what it is they do. 

For anyone interested in getting to know them better, you should check these links out.

https://careoncology.com/faq/

https://www.youtube.com/channel/UCzS4BJcCA_LPNczyJl_hyXA

The first link is care oncology's FAQ section on their website.
The second link is Care Oncologys youtube Channel.

As always, what I am most interested in figuring out is the revenue and potential for natural growth.

in the first link I stumbled upon how much it costs roughly for Care Oncologys service.

How much does it cost? Is it reimbursable?

The initial consultation is $925.00. The bundled-cash price of the medications from our partner pharmacy averages $60.00-$100.00 per month.

Follow ups are $330.00 every three months; for a total cost of $2,635 the first year. The subsequent annual costs total $2,040.

 with that, I can start to speculate on the business of Oncology.

For every Patient in the first year is going to bring in $2635

In their Statements they mention in the U.S they have 3000+ Patients, + concerned Family members.

I am going to assume that
A. every Patient will get at least 1 Aristotle Test in their time envolved with Care Oncology.
B. They are achieving the same level of patients in the U.K Chapter.

3000 Patients x $2635 Treatment       = $7,905,000
3000 Patients x $1500 Aristotle Test   = $4,500,000

for a Total of $12,405,000 Revenue From Their U.S.A clinics

Multiply that by 2 for the U.K and we are at $24,810,000  

That is with only 1 year of treatment. I left out the second years treatment out as there are way to many variables in the cancer world to make any assumptions of how long someones treamtment will last..

That right there is what we just bought into with  15,000,000 shares + 8,000,000 more shares based on performance.

Thats not bad. not the best deal, but not bad IMO.

Add in the Covid Revenue which is on track to be here for another couple quarters at least and we are making some good money.

So,

do I like what we are doing? 

yes,  I feel that the Oncology business which we just propelled ourselves into is a MASSIVE market, and to start out of the gate and already have access to thousands of patients is great. It will help us continue to validate Aristotle, as well as give us the ability to offer the whole spectrum of cancer treatment and make ALOT of money

Do i like how we got here?

Absolutely not. They left alot of us here in the dark not knowing which way we are going, expecting the "BIG RELEASE" and instead got Technical issues and news that we just diluted shares buying some company no one has heard of.  Was quite disapointing and confusing TBH

What do i expect going forward?

As stated in the MD&A (which I highly reccomend everyone read, as it is a great source of information.) it states that in the next couple weeks, we are going to be told more about the AVRT Program and how all of this is going to play out. 

At bare minimum I expect that. 

I also expect to hear about the companies plans to attract these "major employers" or "Hospital Networks"

We have 7 million dollars in Cash.  I expect hear how we are going to use it to grow.

What is the point of having all of this cash and not use it for advertising and marketing strategies?  

Maybe use it to buy another couple clinics?  

At this point, they have a lot of options and a lot of potential to grow very big very quick. especially with a product like they have.


We will all see what the future has in store for SZLS. 

The crystal ball is a little foggy right now, but it will clear up, and we will all see if Mr. Tripp and his new team of Oncologists have what it takes to grow.

Good luck to all,

Cheers, 

Bully










<< Previous
Bullboard Posts
Next >>